THAC, The Healthy Aging Company, is a French and US-based privately-owned biopharmaceutical company which has the ambition to develop a range of first-in-class drug candidates targeting T2DM and its complications.


THAC aims to change the way patient care and healthy aging are addressed. THAC is primarily focused on Type 2 Diabetes Mellitus, a chronic disease with still unmet medical needs, as claimed by health agencies.

♦ Its pipeline could lead to potential real game changers for patient care and disease management. THAC is primarily focused on Type 2 Diabetes Mellitus, a condition with still unmet medical needs.

THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations).

THAC drug candidates have a unique and innovative mechanism of action that targets oxidation and inflammation, which restores the composition of microbiota, and the insulin sensitivity.

THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death and prevent T2DM complications ; peripheral neuropathy is a severe complication for which there is no treatment available; e.g., diabetic foot wounds and amputations.

Type 2 Diabetes Mellitus could be boosted by an altered composition of microbiota

A disequilibrated diet  is associated to a deregulation of the gut microbiota which boost T2DM.

Bacteria present in our ogut microbiota, are essential not only for our digestion, but also for the body equilibrium and homestasis. The perturbation of their function lead to the risk of developing long term pathologies.

Recently, accumulated evidence has suggested that the intestinal microbiota plays an important role in the pathogenesis of T2DM as a potential novel contributor.The adult human intestine is colonized by about 100 trillion bacteria, which is about 10 times the number of total cells in the human body[]. Recent evidence suggests that the intestinal microbiota composition is associated with obesity and T2DM. Ley et al[Their results showed that patients with T2DM had a moderate degree of gut microbial dysbiosis, a reduction in the abundance of some butyrate-producing bacteria, and an increase in various opportunistic pathogens.

Gut bacterial microbiome dysbiosis in type 2 Diabetes Mellitus (T2DM) has been reported,

Gut microbiota is playing a role in T2DM. Western diet (WD) is one of the major culprits of metabolic disease including type 2 diabetes with gut microbiota playing an important role in modulating effects of the diet, There is growing evidence that dysbiosis of the gut microbiota is associated with the pathogenesis of both intestinal and extra-intestinal disorder. Some studies suggest dysbiosis is caused by complex changes resulting from interactions of hundreds of different microbes

he microbiome has been associated with pathophysiology of most chronic diseases. Type 2 diabetes (T2D) is no exception to this rule. Indeed, there is evidence for the effects of microbiota on glucose metabolism in both preclinical animal models of T2D and in healthy animals. Therefore, there is considerable interest in potential use of microbiota in clinical applications for understanding and treating T2D. At first glance, however, the microbiome literature on T2D appears chaotic and concerns have been raised about variability of the results. Different taxa are reported to be associated with T2D in different studies. Furthermore, a recent large study observed that different microbes were found associated with the same metabolic outcomes in different geographical areas [

]. While this might appear somewhat discouraging it is important to remember that discrepancies between results and disagreements about interpretations are common features of any emerging field in science. As a research community, we should not shy away from these problems, rather understand which aspects of the current literature are robust and which ones are not. A key issue moving forward is to identify properties of the microbiome and T2D that contribute to this apparent lack of reproducibility. In this review, we researched recent literature regarding microbiome in type 2 diabetes patients and summarize the most reliable findings.

2. Bacteria involved in T2D
Out of 42 human observational studies that investigated T2D and the bacterial microbiome, the majority of studies reported associations between specific taxa and disease or its phenotypes (see Supporting Table 1 and “Search strategy and selection criteria” below). However, only a handful reported similar results. Among the commonly and consistently reported findings, the genera of Bifidobacterium, Bacteroides, Faecalibacterium, Akkermansia and Roseburia were negatively associated with T2D, while the genera of Ruminococcus, Fusobacterium, and Blautia were positively associated with T2D (Fig. 1). Lactobacillus genus, while frequently detected and reported, shows the most discrepant results among studies. Interestingly, different macro-metrics of microbial communities, such as several indexes of diversity and the Bacteroidetes/Firmicutes ratio that have been previously suggested as markers of metabolic disease did not show consistent associations with T2D (Table 1).

Multiple molecular mechanisms of gut microbiota contribution to metabolic disease and T2D have been recently reviewed elsewhere [

]. Microbiota modulates inflammation, interacts with dietary constituents, affects gut permeability, glucose and lipid metabolism, insulin sensitivity and overall energy homeostasis in the mammalian host (Fig. 2).

ole of gut microbiota in type 2 diabetes pathophysiology lancet, 2020)

Human Gut Microbiota

ALF-5755 directly acts on gut microbiota

Gut Microbiota, inflammation and insulin resistance